Monitoring project of Anlotinib Hydrochloride Capsules (Fu Kewei)

Study on Multi-center, forward-looking, non-intervention safety re-assessment registration of Anlotinib Hydrochloride Capsules (Fu Kewei)

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044367

Enrollment

Unknown

Registered

2021-03-17

Start date

2021-05-10

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer, soft tissue sarcoma, thyroid like cancer or other

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with non-small cell lung cancer, soft tissue sarcoma, thyroid like cancer,or who evaluated will benefit from the treatment with Anlotinib Hydrochloride Capsules; (2) Voluntarily join the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who have been confirmed to be allergic to Anlotinib Hydrochloride Capsules and/or its excipients; (2) pregnant or lactating women; (3) patients with contraindications to Anlotinib Hydrochloride Capsules; (4) The investigator believes that it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
adverse event;Serious adverse event;	—

Secondary

Measure	Time frame
Objective remission rate;Progression-free survival;Overall survival time;	—

Countries

China

Contacts

Public ContactFeng Jifeng

Jiangsu Cancer Hospital

fjif@vip.sina.com+86 13901581264

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026